PharmTech Drug Digest 11.20
News|Articles|March 26, 2015

Recipharm and Adroit Science Collaborate to Expand Development Services

Adroit Science AB will support Recipharm’s pharmaceutical development with solid-state characterization services.

 

Recipharm AB and Adroit Science AB have formed a new strategic collaboration to expand their service offering. Adroit Science AB will support Recipharm’s pharmaceutical development with solid-state characterization services.  The combination of both companies’ expertise in formulation development, API development, chemical analysis, and solid-state characterization, will improve speed and reduce development costs, while improving quality.

Carl-Johan Spak, executive vice-president, Development & Technology at Recipharm, commented in a press release that the addition of development services from Adroit provides a competitive offering that will help customers to progress their projects more efficiently, including complete development from molecule to product.  Adroit Science AB has established itself as a provider of solid-state characterization services in Northern Europe.

According to Hans Gredeby, CEO of Adroit Science AB, Adroit Science and Recipharm have already cooperated in a number of projects and this partnership marks the next step in the mutual development of both companies’ relationship.

Source: Recipharm


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.